Efficacy and Safety of Tamibarotene (OAM80) for Alzheimer's Disease

NCT ID: NCT01120002

Last Updated: 2011-07-22

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 50 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-05-31
• Study Completion Date: 2012-12-31

Brief Summary

A double blind, placebo-controlled randomized study to evaluate the efficacy and safety of orally administered Tamibarotene to patients of Alzheimer's Disease

Detailed Description

Tamibarotene is a synthetic retinoid presently approved in Japan for the treatment of APL, which has a higher receptor selectivity and activity for the Retinoic Acid Receptor subtypes compared to the natural retinoid.

Tamibarotene decreased insoluble amyloid-beta (Ab) 42 deposition in APP mice, and also increased TTR, VAChT and ACh in the brain of SAMP8 mice, which suggest the enhancement of neurotransmission. In the behavioral model such as reduced anxiety of SAMP8 mice and rat passive avoidance test, tamibarotene showed improvement.

Tamibarotene as in other retinoids are known to moderate the immune system and reduce inflammatory cytokines and chemokines, which may control the excessive stimulation of astrocyte and microglia around the Ab plaque. Tamibarotene reduced cytokines and showed clinical efficacy in the rat experimental autoimmune encephalitis model.

Furthermore, retinoids are known to have critical roles during the regeneration stage in the differentiation from neural stem cells (NSC).

In spinal cord injured rats treated with tamibarotene showed better recovery compared to the control.

By these preclinical results, we plan by this study to evaluate the efficacy together with the safety of tamibarotene to the patients of Alzheimer's Disease.

Tamibarotene is used clinically in Japan since 2005. It's side effects are known to be similar to that of other clinically used retinoids.

Conditions

Alzheimer's Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Placebo pill

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Two Tamibarotene 2 mg or placebo tablet per day, once daily.

Tamibarotene

Group Type: ACTIVE_COMPARATOR

Tamibarotene

Intervention Type: DRUG

Two Tamibarotene 2 mg or placebo tablet per day, once daily.

Interventions

Tamibarotene

Two Tamibarotene 2 mg or placebo tablet per day, once daily.

Intervention Type: DRUG

Placebo

Two Tamibarotene 2 mg or placebo tablet per day, once daily.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Japanese patients who are diagnosed as probable Alzheimer' Disease according to NINCDS-ADRDA criteria
• Diagnosed by brain diagnostic imaging (CT, MRI) within six months before the consent and no occurrence of the event after that to suggest cerebral vascular disease
• Mild to Moderate Alzheimer's Disease of MMSE from 10 to 26
• Age from 55 to 80
• Treated for a minimum of 12 weeks with a stable dose of donepezil and willing to continue the same during the trial period
• For women Menopause ≥ 2 years
• For men contraceptive measures are required during the study and after 6 months
• In principle patients should be living at their home in the presence of a caregiver who is defined as a healthy person in contact with the patient for more than 10 hours a week, could provide required information of the behavior and activities of daily living, accompany all the clinical examination, and supervise the handling and administration of the drug throughout the study period.
• Patients who could take pills as a whole
• Patient, caregiver and patient surrogate are able and willing to comply with study visits and procedures per protocol, understand, sign, and date the written voluntary informed consent form

Exclusion Criteria

• Any cause of dementia not due to Alzheimer's disease
• Past history of other central nervous condition or psychiatric disease
• Symptom of depression and drug addiction
• Impairment in the physical function by other factor than the Alzheimer's Disease
• Patients who are expected to move in to care facilities during the study period
• triglyceride > 400 mg/dL

• Minimum Eligible Age: 55 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Osaka City University

OTHER

Sponsor Role: lead

Responsible Party

Department of Geriatrics and Neurology, Osaka City University Graduate School of Medicine

Principal Investigators

Takami Miki, M.D.

Role: PRINCIPAL_INVESTIGATOR

Department of Geriatrics and Neurology, Osaka City University Graduate School of Medicine

Locations

Osaka City University Hospital

Osaka, , Japan

Site Status: RECRUITING

Countries

Japan

Central Contacts

Takami Miki, MD

Role: CONTACT

""miki."@med.osaka-cu.ac.jp"

+81-6-6645-212

Facility Contacts

Center for Drug&Food Clinical Evaluation

Role: primary

morikka@med.osaka-cu.ac.jp

+81-6-6645-344

References

Shudo K, Fukasawa H, Nakagomi M, Yamagata N. Towards retinoid therapy for Alzheimer's disease. Curr Alzheimer Res. 2009 Jun;6(3):302-11. doi: 10.2174/156720509788486581.

Reference Type: BACKGROUND

PMID: 19519313 (View on PubMed)

Other Identifiers

OAM80-01

Identifier Type: -

Identifier Source: org_study_id